Page 5 - Study Start News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DGAP-News: Heidelberg Pharma berichtet über das erste Halbjahr 2021 vom 08.07.2021, 07:11 Uhr Bild: pixabay.com Heidelberg Pharma berichtet über das erste Halbjahr 2021 08.07.2021 / 07:11 PRESSEMITTEILUNG Heidelberg Pharma berichtet über das erste Halbjahr 2021 - HDP-101: Studienantrag für klinische Studie von der FDA im Februar 2021 genehmigt; Studienzentren bereiten sich auf Aufnahme des ersten Patienten vor, Studienantrag bei Paul-Ehrlich-Institut in Deutschland eingereicht - Neue präklinische Daten zum immunmodulatorischen Potenzial von Antikörper-Amanitin-Konjugaten auf der AACR-...

ADELAIDE, AUS, June 4, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient Avance Clinical announced the results of their

Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand The leading Australian CRO Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023. BriefingWire.com, 5/09/2021 - ADELAIDE, AUS, May 7, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet th...

Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand ADELAIDE, AUS, May 7, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023. Avance Clinical is accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR). This accreditation recognizes that Avance Clinical has the CRO resources and ...

ADELAIDE, AU, Apr 22, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been invited to present on the future of decentralized clinical trials at the Oracle Health Sciences Connect conference. Title: Decentralized Trials - No Going Back Link: https://www.oracle.com/in/industries/life-sciences/health-sciences-connect/sessions/ Time: 23 April, 2021 - 3.05 pm (Australia/Adelaide ACST). Avance Clinical CEO Yvonne Lungershausen, shared the company's insights on the future of Decentralized Clinic...